ASH Abstracts Are Out, and They’re Not Helping Biopharma
Research - The NASDAQ Biotech Index Fund (IBB) is down 1.5%, the SPDR S&P Biotech ETF (XBI) down 3% and testing its 200-week moving average and current … Continue Reading
Premium: Read NowResearch
One Asset, Two Settings
Research - In 2014, Valeant Pharmaceuticals (VRX) divested of its filler and toxin aesthetics assets to Galderma, now part of Nestle, for $1.4 billion. The deal included … Continue Reading
Premium: Read Now
Depomed is Still on the Auction Block
Research - The buyout rumors around Depomed (DEPO) continue to swirl, with DealReporter on Wednesdaymorning saying that the company is in discussion with suitors. Depomed rebuked Horizon … Continue Reading
Premium: Read Now
Updates on Some Recent Ideas
Research - Marinus Pharmaceuticals (MRNS) finally released top-line results from their small study of ganaxolone in PCDH19 this morning. Recall we covered this in our August webinar … Continue Reading
Premium: Read Now
Webinar: This Fall’s Medical Conferences
Research - A recording of last night’s strategy webinar is now available. Click here for the recording. Thanks to those of you who attended on a Thursday … Continue Reading
Premium: Read Now
Product Improvements and a Trial Start at Bluebird Bio
Research - We’ve had some questions about this month’s Healthcare Huddle, which will take place on the 22nd(the third full-week Thursday in the month), and what topics … Continue Reading
Premium: Read Now
CNS Is In the News: Updates from PropThink’s August Webinar
Research - A few quick updates from our CNS webinar last month. Sage Therapeutics (SAGE) announced that SAGE-547 has received Breakthrough Therapy Designation for Postpartum Depression based … Continue Reading
Premium: Read Now